Clinical trials: Chest--Diseases
Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation.
- Conditions
- Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II
- Trial name
- NCT05696782
- Testing
- Durvalumab, the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30), COPD Assessment Test (CAT)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Adenocarcinoma of the Lung, Large Cell Lung Cancer
Photodynamic Therapy in Treating Patients With Lung Cancer
This phase I trial is studying the side effects and best dose of photodynamic therapy using HPPH in treating patients with lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT01668823
- Testing
- HPPH, photodynamic therapy, therapeutic bronchoscopy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Italian Lung Cancer Screening Trial (ITALUNG)
ITALUNG is a RCT for the evaluation of the efficacy of lung cancer screening with low-dose Computer Tomography (LDCT) , carried out in three screening centers in Florence, Pisa and Pistoia districts of the Tuscany region of…
- Trial name
- ITALUNG (NCT02777996)
- Testing
- Low Dose Computed Tomography
- Where
- Italy
- Volunteers
- 3,106 people
- Sponsor
- Cancer Prevention and Research Institute, Italy
Lung Cancer, Lung Cancer Metastatic
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.
- Conditions
- Lung Cancer, Lung Cancer Metastatic, Brain Metastases, Brain Metastases, Adult
- Trial name
- NCT05419076
- Testing
- Stereotactic Radiosurgery, Cerebrospinal fluid collection
- Where
- 7 sites in United States
- Volunteers
- 62 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Respiratory Distress Syndrome
Effect of Continuous Anterior Chest Compression on Ventilation/Perfusion Ratio and Hemodynamics
Intro: The mortality of acute respiratory distress syndrome (ARDS) remains high (40%), and may be aggravated by ventilation-induced lung injury (VILI), the main mechanisms of which are: 1. Anterior region overdistension, 2.
- Trial name
- HemodyCACC (NCT06699017)
- Testing
- Continuous anterior chest compression
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Solid Tumor, Cancer, Lung
Exploratory Drug Interaction Study Between SMIs and DOACs
The main objective of this study is to investigate the effect of small molecule inhibitors (SMIs), used in targeted therapy for tumours, on direct oral anticoagulants (DOACs).
- Trial name
- NCT05732350
- Where
- 2 sites in Netherlands
- Volunteers
- 37 people
- Sponsor
- Maastricht University Medical Center
Stage III Non-Small Cell Lung Cancer
Hypofractionated Intensity Modulated Chemoradiotherapy to Treat Locally Advanced Non-Small Cell Lung Cancer
Locally advanced non-small cell lung cancer can be treated successfully with chemotherapy and radiation. However, the cure rate is low.
- Trial name
- NCT00938418
- Testing
- Dose escalated, accelerated, hypofractionated radiotherapy
- Where
- 3 sites in Singapore
- Volunteers
- 43 people
- Sponsor
- National University Hospital, Singapore
Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
- Trial name
- NCT07361510
- Testing
- Pumitamig, Pembrolizumab
- Where
- 283 sites in United States, Argentina and 34 more
- Volunteers
- 750 people
- Sponsor
- Bristol-Myers Squibb
Acute Coronary Syndrome, Chest Pain
Use of Visual Decision Aid for Shared Decision Making in Chest Pain
This study aims to evaluate the use of the chest pain choice (CPC) decision aid as a tool to facilitate discussion between the patient and his/her attending physician with regard to subsequent management plans.
- Conditions
- Acute Coronary Syndrome, Chest Pain, Myocardial Infarction, Angina Pectoris
- Trial name
- NCT03674021
- Testing
- Chest Pain Choice visual aid
- Where
- Singapore
- Volunteers
- 18 people
- Sponsor
- National University Hospital, Singapore
Non Small Cell Lung Cancer
Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02317016
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Lung Cancer
Predicting Symptom Trajectories After Thoracoscopic Lung Cancer Surgery Using an Interpretable Machine Learning Model
Patients suffer from a variety of symptoms after thoracoscopic surgery. However, there is a lack of validated predictive tools to identify potentially high-risk patients.
- Trial name
- NCT06771947
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Guangdong Provincial People's Hospital
Carcinoma, Non-Small-Cell Lung
Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer
Concurrent or sequential chemoradiotherapy has been recommended as the standard treatment for locally advanced and unresectable non-small cell lung cancer (NSCLC). However, its efficacy remains to be improved.
- Trial name
- NCT05306847
- Testing
- Sintilimab, Anlotinib
- Volunteers
- 93 people
- Sponsor
- Peking Union Medical College Hospital
Cancer, Non Small Cell Lung Cancer
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
This exploratory clinical study is designed to obtain pre-therapeutic imaging assessments using positron emission tomography (PET) imaging in 21 patients with Stage IIIB/IV or recurrent non-small cell lung cancer (NSCLC) and an…
- Trial name
- NCT00708448
- Testing
- PET Imaging, Erlotinib, Bevacizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah
Non-small Cell Lung Cancer
A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer
The trial was designed to compare the effectiveness of radical resections of lung cancer plus adjuvant chemotherapies and perioperative chemotherapies in the patients with N2 non-small cell lung cancer
- Trial name
- NCT03451526
- Testing
- Surgeries
- Where
- 10 sites in China
- Volunteers
- 2,929 people
- Sponsor
- Tang-Du Hospital
Pain, Postoperative, Thoracic Diseases
Liposomal Bupivacaine for Pain Control Following Thoracic Surgery.
The aims of the study are to compare the effectiveness and postoperative outcomes of liposomal bupivacaine vs plain bupivacaine following video-assisted thoracoscopic surgery.
- Conditions
- Pain, Postoperative, Thoracic Diseases, Local Anesthetics Causing Adverse Effects in Therapeutic Use, Opioid Dependence
- Trial name
- NCT03036085
- Testing
- Liposomal bupivacaine, Bupivacaine, Epinephrine
- Volunteers
- 200 people
- Sponsor
- Massachusetts General Hospital
NSCLC (Non-small Cell Lung Cancer), Hyperprogression
Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial
In metastatic NSCLC patients with PD-L1 expression ≥50%, a circulating immature (CD10-) LDNs level of ≥30.5% confers a high risk of hyperprogression (HPD) with first line single-agent immune-checkpoint inhibitors (SA-ICI).
- Trial name
- HYPERBOLIC (NCT07274384)
- Testing
- chemotherapy plus cemiplimab, Cemiplimab
- Volunteers
- 74 people
- Sponsor
- Università Vita-Salute San Raffaele
Bone Metastases
MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors
The objective of this trial is to evaluate the safety and effectiveness of MRgFUS in the treatment of metastatic bone tumors.
- Trial name
- NCT00350233
- Testing
- ExAblate 2000
- Where
- 2 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- InSightec
Malignant Pleural Mesothelioma
Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
The purpose is to evaluate the activity and feasibility of a two drug regimen which is partly orally and partly intravenous in advanced pleural mesothelioma.
- Trial name
- NCT00272558
- Testing
- Carboplatin and Vinorelbine
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Lung Cancer
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00041015
- Testing
- cisplatin, etoposide, topotecan hydrochloride
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Case Comprehensive Cancer Center
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.